R. Nordal and S. Thoresen, Uterine sarcomas in Norway 1956???1992: Incidence, survival and mortality, European Journal of Cancer, vol.33, issue.6, pp.907-918, 1990.
DOI : 10.1016/S0959-8049(97)00040-3

S. Brooks, M. Zhan, T. Cote, and C. Baquet, Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989???1999, Gynecologic Oncology, vol.93, issue.1, pp.204-212, 1989.
DOI : 10.1016/j.ygyno.2003.12.029

R. Koivisto-­?korander, J. Martinsen, E. Weiderpass, A. Leminen, and E. Pukkala, Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: Results from NORDCAN and NOCCA databases, Maturitas, vol.72, issue.1, pp.56-60, 2012.
DOI : 10.1016/j.maturitas.2012.01.021

S. Shah, J. Jagannathan, K. Krajewski, O. Regan, K. George et al., Uterine Sarcomas: Then and Now, American Journal of Roentgenology, vol.199, issue.1, pp.213-236
DOI : 10.2214/AJR.11.7287

S. Ueda, D. Kapp, M. Cheung, J. Shin, K. Osann et al., Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths, American Journal of Obstetrics and Gynecology, vol.198, issue.2, 2008.
DOI : 10.1016/j.ajog.2007.08.075

F. Felix, A. Cook, L. Gaudet, M. Rohan, T. Schouten et al., The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium, British Journal of Cancer, vol.50, issue.3, pp.218-219
DOI : 10.1023/A:1008946825313

K. Czes?-nin and Z. Wronkowski, Second malignancies of the irradiated area in patients treated for uterine cervix cancer, Gynecologic Oncology, vol.6, issue.4, pp.309-324, 1978.
DOI : 10.1016/0090-8258(78)90037-9

S. Schwartz and D. Thomas, A case-­?control study of risk factors for sarcomas of the uterus. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer, pp.2487-92, 1989.

H. Kobayashi, The biology of uterine sarcomas: A review and update, Molecular and Clinical Oncology, 2013.
DOI : 10.3892/mco.2013.124

B. Fisher, J. Costantino, C. Redmond, E. Fisher, D. Wickerham et al., Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, JNCI Journal of the National Cancer Institute, vol.86, issue.7, pp.527-564, 1994.
DOI : 10.1093/jnci/86.7.527

U. Magriples, F. Naftolin, P. Schwartz, and M. Carcangiu, High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients., Journal of Clinical Oncology, vol.11, issue.3, pp.485-90, 1993.
DOI : 10.1200/JCO.1993.11.3.485

J. Chan, M. Manuel, M. Cheung, K. Osann, A. Husain et al., Breast cancer followed by corpus cancer: Is there a higher risk for aggressive histologic subtypes?, Gynecologic Oncology, vol.102, issue.3, pp.508-520, 2006.
DOI : 10.1016/j.ygyno.2006.01.014

C. Tropé, V. Abeler, and G. Kristensen, Diagnosis and treatment of sarcoma of the uterus. A review, Acta Oncologica, vol.20, issue.6, pp.694-705
DOI : 10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7

D. Baird, D. Dunson, M. Hill, D. Cousins, and J. Schectman, High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence, American Journal of Obstetrics and Gynecology, vol.188, issue.1, pp.100-107, 2003.
DOI : 10.1067/mob.2003.99

S. Cramer and A. Patel, The Frequency of Uterine Leiomyomas, American Journal of Clinical Pathology, vol.94, issue.4, 1990.
DOI : 10.1093/ajcp/94.4.435

C. Juang, M. Yen, H. Horng, N. Twu, H. Yu et al., Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma, Eur J Gynaecol Oncol, vol.27, issue.4, pp.370-374, 2006.

N. Yilmaz, I. Sahin, S. Kilic, E. Ozgu, T. Gungor et al., Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population, Eur J Gynaecol Oncol, vol.30, issue.4, pp.412-416, 2009.

T. Group, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-­?up, Ann Oncol, vol.25, issue.3, pp.102-114, 2014.

K. Seki, T. Hoshihara, and I. Nagata, Leiomyosarcoma of the Uterus: Ultrasonography and Serum Lactate Dehydrogenase Level, Gynecologic and Obstetric Investigation, vol.33, issue.2, pp.114-122, 1992.
DOI : 10.1159/000294861

A. Goto, S. Takeuchi, K. Sugimura, and T. Maruo, Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus, International Journal of Gynecological Cancer, vol.12, issue.4, pp.354-61, 2002.
DOI : 10.1046/j.1525-1438.2002.01086.x

G. Bogani, W. Cliby, and G. Aletti, Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: A systematic review and meta-analysis, Gynecologic Oncology, vol.137, issue.1
DOI : 10.1016/j.ygyno.2014.11.011

J. Park, D. Kim, J. Kim, Y. Kim, Y. Kim et al., The Impact of Tumor Morcellation During Surgery on the Outcomes of Patients with Apparently Early Low-Grade Endometrial Stromal Sarcoma of the Uterus, Annals of Surgical Oncology, vol.90, issue.12, pp.3453-61, 2011.
DOI : 10.1245/s10434-011-1751-y

C. Bonneau, I. Thomassin-­?naggara, S. Dechoux, A. Cortez, É. Darai et al., Value of ultrasonography and magnetic resonance imaging for the characterization of uterine mesenchymal tumors, Acta Obstetricia et Gynecologica Scandinavica, vol.18, issue.3, pp.261-269, 2014.
DOI : 10.1111/aogs.12325

K. Tamai, T. Koyama, T. Saga, N. Morisawa, K. Fujimoto et al., The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas, European Radiology, vol.181, issue.4, pp.723-753, 2008.
DOI : 10.1007/s00330-007-0787-7

K. Sato, N. Yuasa, M. Fujita, and Y. Fukushima, Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma, American Journal of Obstetrics and Gynecology, vol.210, issue.4
DOI : 10.1016/j.ajog.2013.12.028

I. Thomassin-­?naggara, S. Dechoux, C. Bonneau, A. Morel, R. Rouzier et al., How to differentiate benign from malignant myometrial tumours using MR imaging, European Radiology, vol.25, issue.8, pp.2306-2320, 2013.
DOI : 10.1007/s00330-013-2819-9

T. Nagai, Y. Takai, T. Akahori, H. Ishida, T. Hanaoka et al., Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass, SpringerPlus, vol.3, issue.1, p.678, 2014.
DOI : 10.3109/0284186X.2012.689111

G. Zhang, H. Zhang, X. Tian, and H. Zhang, Magnetic resonance and diffusion-weighted imaging in categorization of uterine sarcomas: correlation with pathological findings, Clinical Imaging, vol.38, issue.6, pp.836-880, 2014.
DOI : 10.1016/j.clinimag.2014.06.004

F. Smith, G. Cherryman, A. Bayliss, W. Fullerton, A. Law et al., A comparative study of the accuracy of ultrasound, X-ray CT and low field MRI in the demonstration of cervical and uterine malignancy, Magnetic Resonance Imaging, vol.7, issue.6, pp.677-686, 1989.
DOI : 10.1016/0730-725X(89)90537-7

J. Park, J. Han, I. Hyun, B. Lee, and Y. Moon, Case of uterine leiomyoma showing fludeoxyglucose uptake on F-18 fludeoxyglucose positron emission tomography/computed tomography, Journal of Obstetrics and Gynaecology Research, vol.45, issue.1, pp.1261-1265, 2010.
DOI : 10.1111/j.1447-0756.2010.01307.x

Z. Zhao, Y. Yoshida, T. Kurokawa, Y. Kiyono, T. Mori et al., 18F-FES and 18F-FDG PET for Differential Diagnosis and Quantitative Evaluation of Mesenchymal Uterine Tumors: Correlation with Immunohistochemical Analysis, Journal of Nuclear Medicine, vol.54, issue.4, pp.499-506, 2013.
DOI : 10.2967/jnumed.112.113472

T. Cancer, Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 1 edition. Tavassoéli FA, Devilee P, editors. Lyon: World Health Organization, 2003.

W. Peters, D. Howard, W. Andersen, and D. Figge, Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential, Obstetrics & Gynecology, vol.83, issue.6, pp.1015-1035, 1994.
DOI : 10.1097/00006250-199406000-00023

L. Guillou, J. Coindre, F. Bonichon, B. Nguyen, P. Terrier et al., Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma., Journal of Clinical Oncology, vol.15, issue.1, pp.350-62, 1997.
DOI : 10.1200/JCO.1997.15.1.350

E. Bastiaannet, H. Groen, P. Jager, D. Cobben, W. Van-der-graaf et al., The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis, Cancer Treatment Reviews, vol.30, issue.1, 2004.
DOI : 10.1016/j.ctrv.2003.07.004

C. To, FIGO staging for uterine sarcomas 104:179], International Journal of Gynecology and Obstetrics Int J Gynecol Obstet, vol.106, issue.3, p.277, 2009.

E. Ricciardi, P. Maniglio, R. Marziani, A. Frega, and M. Moscarini, Gynecologic sarcoma: a clinico-­?pathological review, Eur J Gynaecol Oncol, vol.34, issue.5, pp.379-86, 2013.

B. Bui, J. Blay, F. Bonichon, S. Bonvalot, A. Chevalier-­?place et al., Prise en charge des patients adultes atteints de sarcome des tissus mous, Options et Recommandations, 2006.

N. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874), European Journal of Cancer, vol.44, issue.6, 2008.
DOI : 10.1016/j.ejca.2008.01.019

M. Hensley, N. Ishill, R. Soslow, J. Larkin, N. Abu-­?rustum et al., Adjuvant gemcitabine plus docetaxel for completely resected stages I???IV high grade uterine leiomyosarcoma: Results of a prospective study, Gynecologic Oncology, vol.112, issue.3, pp.563-570, 2009.
DOI : 10.1016/j.ygyno.2008.11.027

D. Hyman, R. Grisham, and M. Hensley, Management of advanced uterine leiomyosarcoma, Current Opinion in Oncology, vol.26, issue.4, pp.422-429
DOI : 10.1097/CCO.0000000000000094

M. Mizuno, Y. Yatabe, A. Nawa, and T. Nakanishi, Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma, International Journal of Clinical Oncology, vol.49, issue.3, pp.348-54, 2012.
DOI : 10.1007/s10147-011-0299-y

P. Reichardt, The treatment of uterine sarcomas, Annals of Oncology, vol.23, issue.suppl 10, pp.151-158
DOI : 10.1093/annonc/mds359

S. Campos, W. Brady, K. Moxley, O. Cearbhaill, R. Lee et al., A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study, Gynecologic Oncology, vol.133, issue.3, pp.537-578
DOI : 10.1016/j.ygyno.2014.02.036

B. Erickson, D. Doo, B. Zhang, W. Huh, and C. Leath, Black race independently predicts worse survival in uterine carcinosarcoma, Gynecologic Oncology, vol.133, issue.2, pp.238-279, 2014.
DOI : 10.1016/j.ygyno.2014.02.041

A. Nagamatsu, N. Umesaki, L. Li, and T. Tanaka, Use of 18F-­?fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas, Oncol Rep, vol.23, issue.4, pp.1069-76, 2010.

N. Umesaki, T. Tanaka, M. Miyama, N. Kawamura, S. Ogita et al., Positron Emission Tomography with 18F-Fluorodeoxyglucose of Uterine Sarcoma: A Comparison with Magnetic Resonance Imaging and Power Doppler Imaging, Gynecologic Oncology, vol.80, issue.3, 2001.
DOI : 10.1006/gyno.2000.6081

M. Murakami, H. Tsukada, M. Shida, M. Watanabe, H. Maeda et al., Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas, International Journal of Gynecological Cancer, vol.16, issue.2, pp.854-60, 2006.
DOI : 10.1111/j.1525-1438.2006.00532.x

Y. Kao, U. Saad, A. Tan, B. Magsombol, and A. Padhy, Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas, Acta Radiologica, vol.52, issue.4, pp.463-469, 2011.
DOI : 10.1258/ar.2011.100509

K. Ho, C. Lai, T. Wu, K. Ng, T. Yen et al., 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.24, issue.Suppl, 2008.
DOI : 10.1007/s00259-007-0533-z

P. Sharma, R. Kumar, H. Singh, S. Jeph, J. Sharma et al., Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma, Nuclear Medicine Communications, vol.33, issue.2, pp.185-90, 2012.
DOI : 10.1097/MNM.0b013e32834e41a6

R. Aguirre, A. , R. Font, C. , B. Guardia et al., Positron emission tomography with 18F-­? fluorodeoxyglucose in patients with uterine sarcoma], Rev Esp Med Nucl, 2007.

J. Park, E. Kim, D. Kim, D. Suh, J. Kim et al., Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma, Gynecologic Oncology, vol.109, issue.2, pp.255-62, 2008.
DOI : 10.1016/j.ygyno.2008.01.030

M. Murakami, H. Tsukada, M. Ikeda, M. Watanabe, T. Muramatsu et al., Availability of whole-­?body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma, p.5100, 2004.

P. Sung, Y. Chen, R. Liu, H. Shieh, P. Wang et al., Whole-­?body positron emission tomography with 18F-­?fluorodeoxyglucose is an effective method to detect extra-­? pelvic recurrence in uterine sarcomas, Eur J Gynaecol Oncol, vol.29, issue.3, pp.246-51, 2008.

E. Ozkan, C. Soydal, M. Araz, and N. Kucuk, Clinical experience of 18F-­?FDG PET/CT in soft tissue and osseous sarcomas, Int J Hematol Oncol, vol.22, pp.163-172, 2012.

. Umesaki, Use of 18F-­?fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas Available from: http://www.spandidos-­?publications.com/or, Oncol Rep, vol.23234, issue.4, 1069.

E. Lee, P. Khong, K. Tse, K. Chan, M. Chu et al., Differentiation of aggressive and indolent subtypes of uterine sarcoma using maximum standardized uptake value, Nuclear Medicine Communications, 2001.
DOI : 10.1097/MNM.0000000000000005

N. Jehanno, M. Wartski, C. Malhaire, P. Fréneaux, S. Petras et al., 18F-FDG PET/CT findings in uterine leiomyomas, European Journal of Nuclear Medicine and Molecular Imaging, vol.54, issue.4, pp.1034-1039, 2014.
DOI : 10.1007/s00259-014-2698-6

Y. Yoshida, Y. Kiyono, T. Tsujikawa, T. Kurokawa, H. Okazawa et al., Additional value of 16??-[18F]fluoro-17??-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET, European Journal of Nuclear Medicine and Molecular Imaging, vol.34, issue.1, pp.1824-1855, 2011.
DOI : 10.1007/s00259-011-1851-8

T. Yamane, A. Takaoka, M. Kita, Y. Imai, and M. Senda, 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma, Annals of Nuclear Medicine, vol.20, issue.Suppl 1
DOI : 10.1007/s12149-012-0597-0